Published in J Pharmacol Exp Ther on June 01, 1976
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A (1986) 3.97
Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A (1996) 3.39
Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A (1997) 3.26
The pharmacology of sigma-1 receptors. Pharmacol Ther (2009) 3.12
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol (1977) 2.61
Excessive morphine requirements after pre-hospital nalbuphine analgesia. J Accid Emerg Med (1999) 2.34
A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol (1980) 1.95
Regulating ankyrin dynamics: Roles of sigma-1 receptors. Proc Natl Acad Sci U S A (2001) 1.92
Differentiation of delta and mu opiate receptor localizations by light microscopic autoradiography. Proc Natl Acad Sci U S A (1980) 1.84
Rate dependency, behavioral mechanisms, and behavioral pharmacology. J Exp Anal Behav (1984) 1.80
Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain. Br J Pharmacol (1981) 1.80
Structure-based discovery of opioid analgesics with reduced side effects. Nature (2016) 1.79
Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect (2004) 1.78
Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) (2004) 1.66
Mu opioids and their receptors: evolution of a concept. Pharmacol Rev (2013) 1.66
Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Natl Acad Sci U S A (1983) 1.65
Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc Natl Acad Sci U S A (1988) 1.65
Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A (2010) 1.63
Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol (1980) 1.56
Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol (2008) 1.55
Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol (2004) 1.51
30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. Pharmacol Ther (2009) 1.50
Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu- and delta-receptors. Br J Pharmacol (1980) 1.47
A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci U S A (1993) 1.46
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Dynorphin A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture. Proc Natl Acad Sci U S A (1987) 1.44
Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther (2009) 1.42
The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol (2006) 1.40
Phencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci U S A (1981) 1.39
Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A (2011) 1.39
mu opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci U S A (1993) 1.39
Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry (2010) 1.39
1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci U S A (1986) 1.37
kappa-Opioid receptor signaling and brain reward function. Brain Res Rev (2009) 1.32
Evidence for an action of morphine and the enkephalins on sensory nerve endings in the mouse peritoneum. Br J Pharmacol (1981) 1.30
Control of guinea pig intestinal electrolyte secretion by a delta-opiate receptor. Proc Natl Acad Sci U S A (1980) 1.27
Membrane-delimited coupling between sigma receptors and K+ channels in rat neurohypophysial terminals requires neither G-protein nor ATP. J Physiol (2000) 1.26
Possible role of distinct morphine and enkephalin receptors in mediating actins of benzomorphan drugs (putative kappa and sigma agonists). Proc Natl Acad Sci U S A (1980) 1.26
Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis (2012) 1.25
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Studies of the mechanism of the antidiarrheal effect of codeine. J Clin Invest (1982) 1.24
kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol (1988) 1.23
When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal (2009) 1.22
Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol (2004) 1.22
Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli. Protein Expr Purif (2006) 1.22
Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci U S A (1984) 1.22
Novel opiate binding sites selective for benzomorphan drugs. Proc Natl Acad Sci U S A (1981) 1.22
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol (1981) 1.21
Comparison of sigma- and kappa-opiate receptor ligands as excitatory amino acid antagonists. Br J Pharmacol (1984) 1.20
Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry (2006) 1.20
Kappa opiate receptors localized by autoradiography to deep layers of cerebral cortex: relation to sedative effects. Proc Natl Acad Sci U S A (1982) 1.19
Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia. Proc Natl Acad Sci U S A (1980) 1.19
Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci U S A (2009) 1.18
Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc Natl Acad Sci U S A (1984) 1.17
CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol (1990) 1.17
The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol (2012) 1.16
A Role for Sigma Receptors in Stimulant Self Administration and Addiction. Pharmaceuticals (Basel) (2011) 1.16
The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol (2005) 1.16
Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol Pharmacol (2010) 1.15
Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists. ACS Chem Neurosci (2009) 1.13
Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous systems. Am J Physiol Cell Physiol (2009) 1.13
(125I)iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor. Proc Natl Acad Sci U S A (1992) 1.13
The σ2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem (2013) 1.13
Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus. Br J Pharmacol (1989) 1.11
Molecular insights into mu opioid pharmacology: From the clinic to the bench. Clin J Pain (2010) 1.10
Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res (2002) 1.10
Sigma-1 receptor chaperones and diseases. Cent Nerv Syst Agents Med Chem (2009) 1.08
Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor. J Biol Chem (2008) 1.07
Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology (2008) 1.07
Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem (2008) 1.07
Evolution of vertebrate opioid receptors. Proc Natl Acad Sci U S A (2008) 1.07
Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol (1983) 1.06
Demonstration of a direct interaction between sigma-1 receptors and acid-sensing ion channels. Biophys J (2010) 1.06
Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther (2010) 1.05
The evolution of vertebrate opioid receptors. Front Biosci (Landmark Ed) (2009) 1.05
The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology (2008) 1.04
Purification of the opiate receptor from rat brain. Proc Natl Acad Sci U S A (1981) 1.04
Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors. Proc Natl Acad Sci U S A (1980) 1.04
Crystal structure of the human σ1 receptor. Nature (2016) 1.03
Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin. Proc Natl Acad Sci U S A (1982) 1.03
Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med (2009) 1.03
Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro. J Neurosci Res (1991) 1.03
Unexpected antagonism in the rat vas deferens by benzomorphans which are agonists in other pharmacological tests. Br J Pharmacol (1981) 1.03
Further studies on opiate receptors that mediate antinoception: tooth pulp stimulation in the dog. Br J Pharmacol (1980) 1.02
K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J Physiol (1999) 1.02
Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology (2012) 1.01
Opioids and their receptors: Are we there yet? Neuropharmacology (2013) 1.01
Effects of opioids on noncholinergic excitatory responses of the guinea-pig isolated ileum: inhibition of release of enteric substance P. Br J Pharmacol (1982) 1.01
Ligand-dependent localization and intracellular stability of sigma-1 receptors in CHO-K1 cells. J Mol Signal (2007) 1.01
Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol (2003) 1.01
Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists. Br J Pharmacol (1987) 1.00
Targeting sigma receptors: novel medication development for drug abuse and addiction. Expert Rev Clin Pharmacol (2009) 0.99
A presynaptic action of the neurosteroid pregnenolone sulfate on GABAergic synaptic transmission. Mol Pharmacol (2003) 0.99
Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol (2014) 0.99
Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs. Br J Clin Pharmacol (1979) 0.99
Analgesic effectiveness of the narcotic agonist-antagonists. Br J Clin Pharmacol (1979) 0.99
Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br J Pharmacol (2001) 0.99
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med (1987) 5.58
Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med (1983) 5.39
Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther (1971) 4.30
Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med (1984) 4.30
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
Posterior tracheal wall perforation during percutaneous dilational tracheostomy: an investigation into its mechanism and prevention. Chest (1999) 2.91
The degradation of polychlorinated biphenyls by micro-organisms. Sci Total Environ (1975) 2.89
Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A (1996) 2.77
Assessing risk factors for transmission of infection. Am J Epidemiol (1991) 2.76
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A (2001) 2.48
Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res (1999) 2.25
Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem (1997) 2.13
Endoscopic papillary balloon dilation vs. sphincterotomy for removal of common bile duct stones: a prospective randomized pilot study. Endoscopy (2001) 2.07
Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry (1998) 2.01
The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. J Pharmacol Exp Ther (1976) 2.00
Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation (2000) 1.84
Selective radiolabeling of cell surface proteins to a high specific activity. Biochemistry (1987) 1.74
Opioid antagonists. Pharmacol Rev (1967) 1.67
The effect of inflation on the cost of journals on the Brandon list. Bull Med Libr Assoc (1980) 1.67
Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies. Neurology (1989) 1.63
Pharmacology of opioids. Pharmacol Rev (1983) 1.62
Efficacy of various forms of fixation of transverse fractures of the patella. J Bone Joint Surg Am (1980) 1.61
Long-term results (7 to 10 years) of endoscopic papillotomy for choledocholithiasis. Multivariate analysis of prognostic factors for the recurrence of biliary symptoms. Gastrointest Endosc (1998) 1.60
The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther (1967) 1.59
Infant botulism: clinical spectrum and epidemiology. Pediatrics (1980) 1.58
Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry (1973) 1.57
Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3). J Pharmacol Exp Ther (1965) 1.57
Extracellular FGF-1 acts as a lens differentiation factor in transgenic mice. Development (1995) 1.53
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol (1996) 1.50
Construction and characterisation of a yeast artificial chromosome library containing three haploid maize genome equivalents. Plant Mol Biol (1992) 1.49
Clinical and pathologic features of cloned transgenic calves and fetuses (13 case studies). Theriogenology (1999) 1.46
Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol (1991) 1.46
Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest (1996) 1.46
Demonstration of tolerance to and physical dependence of N-allylnormorphine (nalorphine). J Pharmacol Exp Ther (1965) 1.45
Methadone--a reevaluation. Arch Gen Psychiatry (1973) 1.44
Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A (1996) 1.41
Patient preferences and the bedside manner. Med Educ (1982) 1.41
An experimental study in the treatment of narcotic addicts with cyclazocine. Clin Pharmacol Ther (1966) 1.40
Evaluation of emission-transmission registration in thoracic PET. J Nucl Med (1994) 1.39
Adenoviral vector infection of the human exocrine pancreas. Arch Surg (1997) 1.38
Assessing patient pain during dental laser treatment. J Am Dent Assoc (1993) 1.37
Therapy for painful cutaneous leiomyomas. J Am Acad Dermatol (1985) 1.36
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol (1996) 1.34
Cerebral blood volume measured with inhaled C15O and positron emission tomography. J Cereb Blood Flow Metab (1987) 1.34
Positron emission tomography in the early diagnosis of Huntington's disease. Neurology (1986) 1.33
America's best medical schools: a critique of the U.S. News & World Report rankings. Acad Med (2001) 1.30
A new HF current generator with automatically controlled system (Endocut mode) for endoscopic sphincterotomy--preliminary experience. Endoscopy (1998) 1.30
Effects of morphine, nalorphine, cyclazocine, and naloxone on the flexor reflex. Int J Neuropharmacol (1967) 1.29
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer (2011) 1.29
Expression of mucin synthesis and secretion in human tracheobronchial epithelial cells grown in culture. Am J Respir Cell Mol Biol (1990) 1.28
DNA affinity labeling of adenovirus type 2 upstream promoter sequence-binding factors identifies two distinct proteins. Mol Cell Biol (1988) 1.27
Evidence for placental abnormality as the major cause of mortality in first-trimester somatic cell cloned bovine fetuses. Biol Reprod (2000) 1.26
Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch Biochem Biophys (1999) 1.26
What are the implications of variation in root hair length on tolerance to phosphorus deficiency in combination with water stress in barley (Hordeum vulgare)? Ann Bot (2012) 1.26
Extracranial-intracranial bypass surgery: hemodynamic and metabolic effects. Neurology (1984) 1.24
A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos (1985) 1.24
The oxygen free radical system: a fundamental mechanism in the production of myocardial necrosis. Prog Cardiovasc Dis (1986) 1.23
Expression of a truncated FGF receptor results in defective lens development in transgenic mice. Development (1995) 1.22
Mitochondrial tyrosine nitration precedes chronic allograft nephropathy. Free Radic Biol Med (2001) 1.19
Salicylate poisoning complicated by fluid retention. Clin Toxicol (1976) 1.15
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature (1985) 1.14
Cloning of a carcinoembryonic antigen gene family member expressed in leukocytes of chronic myeloid leukemia patients and bone marrow. Cancer Res (1990) 1.14
Identification of a downstream sequence and binding protein that regulate adenovirus major late promoter transcription in vitro. J Biol Chem (1988) 1.13
Molecular cloning of a gene belonging to the carcinoembryonic antigen gene family and discussion of a domain model. Proc Natl Acad Sci U S A (1987) 1.12
Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg (1999) 1.12
Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology (1986) 1.12
Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotrophic factors. J Neurochem (1995) 1.10
Testing neural network models of memory with behavioral experiments. Curr Opin Neurobiol (2000) 1.10
Naloxone. Ann Intern Med (1976) 1.10
Characterization of the 5'-terminal structure of simian virus 40 early mRNA's. J Virol (1979) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Characterization of murine carcinoembryonic antigen gene family members. Mamm Genome (1992) 1.09
Effects of ethanol ingestion and dietary fat levels on mitochondrial lipids in male and female rats. Lipids (1978) 1.09
PATHWAY FOR THE DISSIMILATION OF ITACONIC AND MESACONIC ACIDS. J Bacteriol (1961) 1.08
History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol (1979) 1.08
Accelerated coronary arteriosclerosis in cardiac transplant recipients. Transplant Rev (Orlando) (1987) 1.08
Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation (2000) 1.08
Effects of short- and long-term administration of pentazocine in man. Clin Pharmacol Ther (1970) 1.07
Semiochemicals for use with parasitoids: Status and future. J Chem Ecol (1990) 1.06
Development rates of male bovine nuclear transfer embryos derived from adult and fetal cells. Biol Reprod (2000) 1.06
Balance between intake and output of lead in normal individuals. Br J Ind Med (1971) 1.06
Cognitive change following MPTP exposure. Neurology (1990) 1.05
Positron emission tomography and histopathology in Pick's disease. Neurology (1987) 1.05
Biological and toxicological consequences of quinone methide formation. Chem Biol Interact (1993) 1.05
Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. Am J Pathol (1999) 1.05
Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. Diabetologia (2012) 1.04
Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J Immunol (1985) 1.04
Induced abortion and breast cancer risk. Epidemiology (2000) 1.04
Estrogen attenuates integrin-beta(3)-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Circulation (2000) 1.04
Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clin Pharmacol Ther (1968) 1.04
Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors. Cancer Res (1988) 1.03
Glutaric aciduria; presence of glutaconic and beta-hydroxyglutaric acids in urine. Biochem Med (1975) 1.02
Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res (1987) 1.02